CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
B-cell receptor (BCR) signaling has been inferred as an important mechanism for disease progression in chronic lymphocytic leukemia (CLL) and other B-cell malignancies. In response to BCR activation, CLL cells secrete the chemokine CCL3, which fosters interactions between CLL cells and the leukemia microenvironment. CCL3 secretion correlates with expression of the 70-kDa ζ-associated protein (ZAP-70) and responsiveness of the CLL clone to BCR stimulation. Here, we measured CCL3 plasma levels by enzyme-linked immunosorbent assay (ELISA) in 351 CLL patients and examined CCL3 levels for associations with established prognostic markers and time from diagnosis to initial therapy. We found that CCL3 plasma concentrations were strongly associated with established prognostic markers. In a Cox proportional hazards regression model, CCL3 as well as established prognostic markers (immunoglobulin heavy chain variable-region mutation status, CD38 or ZAP-70 cytogenetics, clinical stage) were significantly associated with time to treatment. Multivariable analysis revealed that CCL3 (hazard ratio [HR] = 2.33, P < .0001), advanced clinical stage (HR = 2.75, P = .0025), poor risk cytogenetics (del 17p, HR = 2.38; del11q, HR = 2.36, P = .001), and CD38 expression (HR = 1.43, P = .023) were independent prognostic markers. Collectively, CCL3 is a novel, robust, and independent prognostic marker in CLL that can easily and reliably be measured by ELISA. CCL3 therefore should become useful for risk assessment in patients with CLL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999) · Blood · doi:10.1182/blood.v94.6.1848 · Cited by 2,783
Cited by
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Self-citationTargeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Self-citationBurger, J. A., Keating, M. J., Wierda, W. G., Hartmann, E., Hoellenriegel, J., Rosin, N. Y., de Weerdt, I., Jeyakumar, G., Ferrajoli, A., Cardenas-Turanzas, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70335-3 · Cited by 332
Self-citationB cell receptor signaling in chronic lymphocytic leukemia
Burger, J. A., & Chiorazzi, N. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.002 · Cited by 327
Self-citation
Metadata
- Authors
- Sivina, M., Hartmann, E., Kipps, T. J., Rassenti, L., Krupnik, D., Lerner, S., LaPushin, R., Xiao, L., Huang, X., Werner, L., Neuberg, D., Kantarjian, H., O'Brien, S., Wierda, W. G., Keating, M. J., Rosenwald, A., & Burger, J. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-02-03
- Volume
- 117
- Issue
- 5
- Pages
- 1662-1669
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2124133381
- Cited by
- 127
- References
- 1
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1182/blood-2010-09-307249
- The paper
- Sivina, M., Hartmann, E., Kipps, T. J., Rassenti, L., Krupnik, D., Lerner, S., LaPushin, R., Xiao, L., Huang, X., Werner, L., Neuberg, D., Kantarjian, H., O'Brien, S., Wierda, W. G., Keating, M. J., Rosenwald, A., & Burger, J. A. (2011). CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood-2010-09-307249
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.